enGene details 2026 shareholder meeting vote results

enGene Therapeutics Inc. reported the results of its 2026 Annual General Meeting of shareholders.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

enGene Therapeutics Inc. reported the results of its 2026 Annual General Meeting of shareholders. The meeting was held on June 9, 2026, with 56,196,302 common shares represented, about 83.89% of the 66,989,466 shares outstanding and entitled to vote as of April 28, 2026.

Shareholders voted on the election of directors and on the appointment and remuneration of the auditor. Director nominees, including Philip Astley-Sparke and Ronald H.W. Cooper, each received more than 47.1 million votes “for,” with relatively few “withhold” votes and substantial broker non-votes. The auditor proposal received 56,180,287 votes “for” and 16,015 “withhold.”

8-K Event Classification

2 items: 5.07, 9.01

2 items

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Shares represented at meeting: 56,196,302 shares Participation rate: 83.89% Shares outstanding: 66,989,466 shares +5 more

8 metrics

Shares represented at meeting 56,196,302 shares Common shares present or represented by proxy at 2026 AGM

Participation rate 83.89% Portion of 66,989,466 shares outstanding and entitled to vote

Shares outstanding 66,989,466 shares Common shares outstanding and entitled to vote as of April 28, 2026

Votes for Philip Astley-Sparke 47,112,414 votes For votes in director election, with 306,821 withheld

Votes for Ronald H.W. Cooper 47,329,848 votes For votes in director election, with 89,387 withheld

Auditor proposal for votes 56,180,287 votes Votes for appointment and remuneration of auditor

Auditor proposal withheld 16,015 votes Votes withheld on appointment and remuneration of auditor

Warrant exercise price $11.50 per share Each warrant exercisable for one common share at this price

Key Terms

Annual General Meeting, broker non-votes, Emerging growth company, Proxy Statement, +1 more

5 terms

Annual General Meeting financial

"The 2026 Annual General Meeting of shareholders (the “Annual Meeting”) of enGene Therapeutics Inc."

broker non-votes financial

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Proxy Statement regulatory

"which matters are each described in further detail in the Company’s definitive Proxy Statement"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

Inline XBRL technical

"Cover Page Interactive Data File (Formatted as Inline XBRL)."

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was the quorum at enGene Therapeutics (ENGN) 2026 Annual General Meeting?

The quorum was strong, with 56,196,302 common shares represented. This equaled approximately 83.89% of the 66,989,466 shares outstanding and entitled to vote as of the April 28, 2026 record date, indicating broad shareholder participation.

How did enGene Therapeutics (ENGN) shareholders vote on director elections in 2026?

Shareholders cast large majorities of votes in favor of each director nominee. For example, Philip Astley-Sparke received 47,112,414 votes for and 306,821 withheld, while Ronald H.W. Cooper received 47,329,848 votes for and 89,387 withheld, alongside significant broker non-votes.

What were the auditor proposal voting results for enGene Therapeutics (ENGN)?

For the proposal on appointment and remuneration of the auditor, shareholders cast 56,180,287 votes for and 16,015 votes withheld. There were no broker non-votes recorded for this item, indicating nearly all represented shares voted on the auditor matter.

When was the record date for enGene Therapeutics (ENGN) 2026 Annual Meeting?

The record date for determining shareholders entitled to vote at the 2026 Annual General Meeting was April 28, 2026. As of that date, 66,989,466 common shares were outstanding and eligible to vote on director elections and the auditor proposal.

Which exchanges list enGene Therapeutics (ENGN) common shares and warrants?

enGene Therapeutics’ common shares trade on The Nasdaq Stock Market LLC under the symbol ENGN. Its warrants, each exercisable for one common share at an exercise price of $11.50 per share, trade on Nasdaq under the symbol ENGNW, providing a derivative exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/10/2026 - 04:09 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 09, 2026

    

enGene Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)


British Columbia	001-41854	Not applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4868 Rue Levy, Suite 220
Saint-Laurent, Quebec, Canada		H4R 2P1
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 514 332-4888

    

     Not Applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	ENGN	The Nasdaq Stock Market LLC
Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share	ENGNW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2026 Annual General Meeting of shareholders (the “Annual Meeting”) of enGene Therapeutics Inc. (the “Company”) was held on June 9, 2026 at 8:30 a.m. EDT. A total of 56,196,302 common shares of the Company, no par value (the “Common Shares”) were present or represented by proxy at the Annual Meeting, representing approximately 83.89% of the Company’s 66,989,466 Common Shares that were outstanding and entitled to vote at the Annual Meeting as of the record date of April 28, 2026.

Set forth below, and pursuant to the requirements set out in subsection 11.3 of National Instrument 51-102, are the final voting results for each of the matters submitted to a vote of the shareholders at the Annual Meeting, which matters are each described in further detail in the Company’s definitive Proxy Statement, as filed with the Securities and Exchange Commission on May 8, 2026:

Proposal 1 – Election of Directors



Director Nominee	For	Withhold	Broker Non-Votes
Philip Astley-Sparke	47,112,414	306,821	8,777,067
Ronald H.W. Cooper	47,329,848	89,387	8,777,067
Dr. William Grossman	47,408,163	11,072	8,777,067
Michael Heffernan	47,408,163	11,072	8,777,067

Proposal 2 – Appointment and Remuneration of Auditor


For	Withhold	Broker Non-Votes
56,180,287	16,015	-

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit Number		Description
104		Cover Page Interactive Data File (Formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			ENGENE THERAPEUTICS INC.

Date:	June 10, 2026	By:	/s/ Ronald H. W. Cooper
			Name: Ronald H. W. Cooper Title: Chief Executive Officer and President

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document